KROS vs IMVT vs KRYS vs DAWN vs BEAM

For growth investors, Keros Therapeutics, Inc.

(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus 20. 6% for Day One Biopharmaceuticals, Inc. (DAWN). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Keros Therapeutics, Inc. (KROS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Keros Therapeutics, Inc.

(KROS) is the cheapest at 5. 1x versus Krystal Biotech, Inc. at 43. 4x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +319. 2%, compared to -78. 1% for Keros Therapeutics, Inc. (KROS). Over 10 years, the gap is even starker: KRYS returned +26. 9% versus KROS's -42. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.

(DAWN) is the lower-risk stock at 0. 35β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 505% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Keros Therapeutics, Inc.

(KROS) is pulling ahead at 67. 7% versus 20. 6% for Day One Biopharmaceuticals, Inc. (DAWN). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -67. 8% for Day One Biopharmaceuticals, Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KROS: 781.

4% to $102. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Day One Biopharmaceuticals, Inc.

(DAWN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35)). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DAWN: -8. 4%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KROS is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; KRYS is a small-cap high-growth stock; DAWN is a small-cap high-growth stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.